


Available online at www.frontierjournals.org

FRONTIER JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH





Research Paper

Development and validation of Lvox In RP- HPLC

R.Vikas deshmukh*, V. Kiran kumar¹, P.Aravinda Reddy²



¹ Assistant Professor, Department of Pharmaceutical analysis, Mother Teresa college of Pharmacy, Ghatkesar, Medchal Telangana-501301

ARTICLE INFO

ARTICLE HISTORY

Received 05 December 2023 Received in revised form 10 December 2023 Accepted 12 December 2023 Available online 19 December 2023

Key words:

RP- HPLC, Lvox maleate

ABSTRACT

The goal of this project is to create a credible RP-HPLC method for quantitative assessment of Lvox maleate in drug dose structure, and to evaluate the validity of investigations on the forced corruption of medicines.



strategies: We can simplify the chromatographic conditions by using a $250 \text{ mm} \times 4.6 \text{ mm}$, 5 m C18 Hyperchrome ODS segment, a 70:30 v/v Methanol and phosphate buffer (pH 2.5), a flow rate of 1 ml/min at room temperature, and UV detection at 250 nm.

results: According to the proposed strategy, Lvox needed an estimated 5.94 minutes of upkeep every day. Over a concentration range of 10-50 g/ml, the proposed approach was evaluated for linearity, and a correlation coefficient of 0.998 was found. The expansion of the proposed answer utilising a popular method was rated at 99.62 percent accurate. Research showed that the percent RSD of accuracy was settled on as 0.69. Critical corruption with first-rate purpose between the pinnacles relates to debasement objects and analyte, as shown by the norm and marketed plan provided to hydrolytic and oxidative pressure situations. According to the proposed pressure corruption focus, Lvox is a fragile particle in corrosive, salt, apolitical, and oxidative instances, and is helpless to debasement being subjected to UV radiation and moisture, but maintains its stability below dry intensity (50 °C).

In conclusion, the validated HPLC method provided for quantitatively measuring Lvox maleate in tablet dimension structure is actual, precise, cost-effective, and resilient. For inspection of medicines and its corrupting items in steadiness tests, the developed solidity showing approach may be proposed.

Corresponding author:

R.Vikas deshmukh,Department of Pharmaceutical analysis, Mother Teresa college of Pharmacy,Ghatkesar, Medchal Telangana-501301

EMAIL: draravindareddypurma@gmail.com

1. INTRODUCTION

A chromatographic method's efficacy depends on its ability to integrate the following elements: a constant level, a compact level, a mixture testing shape, a dissolvable motion framework, a part, and an identifiable evidence knowledgeable expert¹.

These factors are always manipulated in any chromatographic method. In the pharmaceutical industry, chromatographic methods are frequently employed to direct comprehensive data analyses.

High-performance liquid chromatography (HPLC) is one of the most widely used chromatographic techniques, with applications ranging from determining the potential of new drug candidates to studying the dynamics and adaptability of manufactured frameworks, defining key concepts, and monitoring finished drug product quality².

In high-performance liquid chromatography (HPLC), a liquid, movable diploma and a finely separated, constant degree are used. For a reasonable cost of improvement, it is necessary to pack liquid at a rate of several pounds per square inch. If the speed at which medicines are distributed between the fixed and adaptive level is mandated by the spread technique, the task of dividing them up can be done more quickly and more practically. Modern liquid chromatography is driven by its most important

²Principal, Mother Teresa college of Pharmacy, Ghatkesar, Medchal Telangana-501301

perceivability, which sets it apart from older methods of segment chromatography. advancements in segment innovation, such as the unreasonable anxiety siphoning device and sensitive finders, have led to the development of speedy and mostly steady liquid element chromatography³.

HPLC is the preferred approach in the field of coherent innovation because to its specificity, robustness, speed, accuracy, and clarity; its negligible personality hindrance; and its many distinct benefits.rapidity (a lot of tests need to be able to be done in a short amount of time).

Figure no. 1 Structure of Luvox

The antidepressant fluvoxamine, marketed variously under the names Luvox and others, is a top-tier selective serotonin reuptake inhibitor (SSRI). Major depressive disorder (MDD) and obsessive-compulsive disorder (OCD) are the most common conditions for which it is prescribed, but it is also used to treat anxiety disorders such OCD, panic disorder, and phobias. The primary purpose of the proposed work is to encourage a new straightforward, careful, authentic, and cost-effective logical technique for assessing Luvox in the form of mass and marketed medication measurements⁴.

2.MATERIALS AND METHOD

Instrumentation

S.No	Instruments And Glass wares	Model		
1	HPLC	WATERS Alliance 2695 separation module, Software: Empower 2, 996 PDA Detector.		
2	pH meter	Labindia		
3	Weighing machine	Sartorius		
4	Volumetric flasks	Borosil		
5	Pipettes and Burettes	Borosil		
6	Beakers	Borosil		
7	Digital ultra sonicator	Labman		

Chemicals

S.No	Chemical	Brand names
1	Fluvoxamine (Pure)	Luvox
2	Water for HPLC	(MERCK)
3	Acetonitrile for HPLC	Merck

Preparation of buffer (pH-2.5)

Ten grams of potassium dihydrogen orthophosphate were dissolved in a thousand milliliter volumetric carafe of double-distilled water until the pH dropped from 2.5 to 0. With double-shaded water, 1NHCl and scope are entirely up to the imprint.

Preparation of working standard solution

One milligram of FLV was prepared in one milliliter of methanol. To acquire the final concentration of 20 g/ml of FLV, a 1.0 ml portion of this arrangement was further diluted with versatile degree.

System suitability parameters

Testing the reproducibility of the chromatographic framework to ensure it is adequate for the study to be carried out is what the framework reasonableness test is all about. The constraints of the framework, such as storage time, unevenness, hypothetical plates, and percentage, informed the development of an RP-HPLC method. The relative deviation of six infusions in terms of fashion was evaluated.

Specificity

In the presence of other components, the ability to evaluate the analyte unambiguously is said to be explicit. The strategy's clarity was achieved through the integration of a mix of FLV's conventional arrangement, promoted detailing, and clear.

Calibration curve

To obtain a concentration range of 10 g/ml to 50 g/ml for FLV, aliquots of the standard arrangement were diluted within the reach of 1.0 ml to 5.0 ml in a development of 10 ml volumetric flagons with the flexible level. The adjusting bend was built by tracing the area under the arc in opposition to the fixation point⁶.

3. RESULT AND DISCUSSION

System suitability parameter

The FLV elution time was reduced to 5.94 minutes thanks to the newly developed, streamlined procedure. A typical chromatogram of modern FLV. Six reconstituted infusions of 10 g/ml preferred have been evaluated for reasonableness constraints within the framework. The results of the obstructions caused by the framework's suitability.

Wt. of Staken (g)	td.Mean area (μV)		Retention time	Asymmetry	Theoretical plates
0.010	601122.33	192 7.56	5.939	1.05	8874

Table 1: System suitability parameters

Specificity

Common FLV chromatograms and test chromatograms reveal that the peak obtained within the standard arrangement and the example arrangement at working fixation are due to medicine, since clean has no peak on the rentention time of FLV. As the example association demonstrates, the created approach is meant to be specific, as no excipients were seen to elute throughout the renewal periods of the specified drugs?




Fig. 2: Typical chromatogram of standard FLV

Degradation parameters	Interval	% Drug un- degraded Exposed Std.
		FLV
Solution state analysis		
Acid degradation (0.1 M HCl)	At 80 °C,	76.77
Base degradation (0.1 M NaOH)	90 min	88.97
Peroxide degradation (3% H2 O2)		86.75
Distill water degradation		79.93
Solid state analysis		
Humidity studies (40 °C/75% RH)	15Days	83.94
Photo stability studies (UV light)	*7day	86.45*
Thermal studies (50 °C)		94.41

Table 2: Force degradation study

Degradation of FLV was estimated to be around 20% in an exposed norm and as an example, and 40% in an acidic hydrolysis condition, demonstrating a very labile nature. In the chromatogram of the test performed under soluble hydrolysis, two additional degradants were identified as the most abundant peaks. The chromatogram of the test conducted beneath acidic hydrolysis showed one more degradant peak. Under unbiased hydrolysis, the test chromatogram showed two major degradants at the top: Deg1 (RRT-0.74) and Deg2 (RRT-0.99). The oxidative hydrolysis test chromatogram showed an additional degradant peak [Deg1 (RRT-0.91)]. When put under pressure, the RRT of contaminations found in BP 2009 does not match up with the

degradant RRTs, which leads to the arrangement of invisible contaminants. When provided to stickiness, depth, and light, a checked and standard FLV exhibits acceptable debasement. Under UV light (ICH recommended), over 93% of tests degraded over the course of a day, and an additional peak was discovered in the chromatogram. power of arrangement country debasement studies have shown that there has been a clear separation of debasement peaks and analyte peaks, demonstrating the explicitness of the look at method for assessment of FLV in the sight of its corruption items. this can be used to evaluate the safety of FLV in mass medication and drug measurement systems.

Precision (% Assay)

The degree to which a medical procedure may be replicated under typical conditions of use is what we call its accuracy. The precision was disseminated as the prevailing style deviation (RSD). Table shows that this method is superior to others for measuring FLV in the absence of interference from the excipients typically included in such medications. The proposed approach is quite accurate, as seen by its low value of general deviation (0.69).

Marketed formulation- Fluvoxin		•		
Wt. taken	AUC of Standard	AUC	of%	Labeled
		Sample	claim*	
(mg)	(μV)	(μV)		
51.67		1202530	99.31	
51.72	1223172	1202705	99.23	
50.92		1180403	98.92	
52.10	1	1220698	99.98	
51.98		1196205	98.20	
50.43		1182163	100.03	
		Mean	99.27	
		±SD	0.68	
		% RSD	0.69	

Table 3: Assay of FLV in marketed formulation

Accuracy

For FLV, the percentage of loss that was restored ranged from 98.34% to 101.36 %, demonstrating the high accuracy of the approach. Table 6 shows the percentages by which the decision to allow recovery was made. Excellent restoration values, as indicated by the reported range of 98%-102%, and all observed facts lie within the crucial range, indicating the accuracy of the developed technique.

Wt. of tablet powder (mg)	Amt. of Std. FLV added (mg)	Amt. of FLV recovered (mg)	% Recoveryof FLV
25.84	3.98	3.97	99.74
25.40	4.40	4.46	101.36
25.88	4.98	4.96	99.60
26.03	5.51	5.46	99.09
26.10	6.05	5.95	98.34
Mean % recovery	Ó		99.62
±SD			1.11
RSD			1.12

Table 4: Recovery study

Sensitivity

Both the limit of detection (LOD) and the lower limit of quantitation (LOQ) were set at 0.109 g/ml and 0.332 g/ml, respectively. The outcomes demonstrate the developed method's acute precision.

Robustness

The low value of mean RSD (1.55), demonstrating the method became demanding and energetic, shows that the substance of the medica.

4. CONCLUSION

The proposed HPLC method is a soundness demonstrating one that is also clever and time-efficient. The high degree of accuracy, reality, and vitality demonstrated by the method's low RSD benefits of approval hurdles. hence, the proposed approach is dynamic, rapid, and precise. The depleted peaks were likewise significantly separated from the analyte peaks. Therefore, the developed method is likely to be used for examining FLV soundness tests at good control laboratories⁹.

5.CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest.

6. ACKNOWLEDGEMENT

We are highly grateful to our Honorable Chairman, Mother Terasa college of Pharmacy, Telangana state for providing the necessary facilities to carry out this research work.

7.REFERENCE

 Casadevall A., Dadachova E., Pirofski L.A. Passive Antibody Therapy for Infectious Diseases. *Nat. Rev. Microbiol.* 2004;2:695–703. doi: 10.1038/nrmicro974.

- 2. Abraham J. Passive Antibody Therapy in COVID-19. *Nat. Rev. Immunol.* 2020;20:401–403. doi: 10.1038/s41577-020-0365-7.
- Casadevall A., Pirofski L.A. The Convalescent Sera Option for Containing COVID-19. J. Clin. Investig. 2020;130:1545–1548. doi: 10.1172/JCI138003.
- 4. Ali S., Uddin S.M., Ali A., Anjum F., Ali R., Shalim E., Khan M., Ahmed I., Muhaymin S.M., Bukhari U., et al. Production of Hyperimmune Anti-SARS-CoV-2 Intravenous Immunoglobulin from Pooled COVID-19 Convalescent Plasma. *Immunotherapy*. 2021;13:397–407. doi: 10.2217/imt-2020-0263.
- 5. Buchacher A., Iberer G. Purification of Intravenous Immunoglobulin G from Human Plasma-Aspects of Yield and Virus Safety. *Biotechnol. J.* 2006;1:148–163. doi: 10.1002/biot.200500037.
- 6. R.Mahesh, M, C., & M, S. (2023). Development and validation of Glyburide In RP- HPLC. Frontier Journal of Pharmaceutical Sciences and Research, 6(2), 17–21.
- 7. V.Uma Maheshwar Rao, & Arjun Goje. (2023). Rp-hplc method development and validation of ketoconazole in bulk and pharmaceutical dosage form: Rp-hplc method development and validation of ketoconazole in bulk and pharmaceutical dosage form. *Frontier Journal of Pharmaceutical Sciences and Research*, *I*(1), 1–8.
- 8. Khodke A, Potale L, Damle M, Bothar a K. A validatedstability indicating HPTLC method for simultaneousestimation of irbesartan and hydrochlorothiazide. Pharmaceutical Methods. 2010;2:39-43.
- 9. P.Sruthi, P.Prapulla, & P.Aravinda Reddy. (2023). A stability indicating RP-HPLC method for estimation of Acebrophvllln Montalukast in bulk dosage forms. *Frontier Journal of Pharmaceutical Sciences and Research*, 6(3), 13–17